Advertisement

Unusual Renal Mass in a Pediatric Patient

Published:November 02, 2022DOI:https://doi.org/10.1016/j.urology.2022.10.012

      Abstract

      Renal cell carcinoma (RCC) is rare in the pediatric population, comprising about 5% of renal neoplasms in children.
      • Ma J
      • Pan C
      • Yin M.
      Translocation renal cell carcinoma in a child previously treated for infantile fibrosarcoma.
      Out of all childhood cases of RCC, translocation RCCs (tRCC) is the most common.

      Translocation renal cell carcinoma - NCI. Published March 17, 2020. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-kidney-tumors/translocation-renal-cell-carcinoma. Accessed September 12, 2022

      It is well described in the literature that exposure to alkylating agents such as cyclophosphamide and/or topoisomerase II inhibitors such as doxorubicin and etoposide, is a risk factor for the development of Xp11 (or TFE3) tRCC.
      • Dreisin A
      • Matrana MR.
      Treating renal cell carcinoma in young adults: challenges and solutions.
      Herein is a case of tRCC development in a patient with history of exposure to topoisomerase II inhibitors and alkylating agents to treat a common childhood malignancy.

      Abbreviations:

      NBL (neuroblastoma), MIBG (iodine-123 meta-iodobenzylguanidine), RCC (renal cell carcinoma), tRCC (translocation renal cell carcinoma), COG (Children's Oncology Group)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ma J
        • Pan C
        • Yin M.
        Translocation renal cell carcinoma in a child previously treated for infantile fibrosarcoma.
        Pediatr Dev Pathol. 2018; 21: 418-422https://doi.org/10.1177/1093526617707849
      1. Translocation renal cell carcinoma - NCI. Published March 17, 2020. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-kidney-tumors/translocation-renal-cell-carcinoma. Accessed September 12, 2022

        • Dreisin A
        • Matrana MR.
        Treating renal cell carcinoma in young adults: challenges and solutions.
        COAYA. 2016; 6: 31-38https://doi.org/10.2147/COAYA.S82799
        • van der Beek JN
        • Geller JI
        • de Krijger RR
        • et al.
        Characteristics and outcome of children with renal cell carcinoma: a narrative review.
        Cancers (Basel). 2020; 12: 1776https://doi.org/10.3390/cancers12071776
        • Argani P
        • Laé M
        • Ballard ET
        • et al.
        Translocation carcinomas of the kidney after chemotherapy in childhood.
        J Clin Oncol. 2006; 24: 1529-1534https://doi.org/10.1200/JCO.2005.04.4693
        • Ogunbiyi MO
        • Rodriguez-Justo M
        • Gaunt T
        • Shankar A.
        Neuroblastoma-associated renal cell carcinoma: a case report and review of the literature.
        J Pediatr Hematol Oncol. 2022; 44: e612-e615https://doi.org/10.1097/MPH.0000000000002251
        • He M
        • Cai J
        • Zhu K
        • et al.
        Renal cell carcinoma in children and adolescents: Single-center experience and literature review.
        Medicine. 2021; 100: e23717https://doi.org/10.1097/MD.0000000000023717
        • van der Beek JN
        • Hol JA
        • Coulomb-l'Hermine A
        • et al.
        Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: a report of the SIOP-Renal Tumor Study Group.
        Int J Cancer. 2021; 148: 2724-2735https://doi.org/10.1002/ijc.33476
        • Geller JI
        • Cost NG
        • Chi YY
        • et al.
        A prospective study of pediatric and adolescent renal cell carcinoma: a report from the children's oncology group AREN0321 study.
        Cancer. 2020; 126: 5156-5164https://doi.org/10.1002/cncr.33173
        • Cook A
        • Lorenzo AJ
        • Salle JLP
        • et al.
        Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy.
        J Urol. 2006; 175: 1456-1460https://doi.org/10.1016/S0022-5347(05)00671-3
        • Ehrlich PF
        • Chi YY
        • Chintagumpala MM
        • et al.
        Results of the first prospective multi-institutional treatment study in children with bilateral wilms tumor (AREN0534): a report from the children's oncology group.
        Ann Surg. 2017; 266: 470-478https://doi.org/10.1097/SLA.0000000000002356
        • Chen H
        • Yang S
        • Qian C.
        Effectiveness of nephron sparing surgery and radical nephrectomy in the management of unilateral wilms tumor: a meta-analysis.
        Front Oncol. 2020; 10 (Available at) (Accessed September 15, 2022)
        • Wang J
        • Li M
        • Tang D
        • Gu W
        • Mao J
        • Shu Q.
        Current treatment for Wilms tumor: COG and SIOP standards.
        World J Pediatr Surg. 2019; 2e000038https://doi.org/10.1136/wjps-2019-000038
        • Rialon KL
        • Gulack BC
        • Englum BR
        • Routh JC
        • Rice HE.
        Factors impacting survival in children with renal cell carcinoma.
        J Pediatr Surg. 2015; 50: 1014-1018https://doi.org/10.1016/j.jpedsurg.2015.03.027
        • Saltzman AF
        • Smith DE
        • Gao D
        • et al.
        How many lymph nodes are enough? Assessing the adequacy of lymph node yield for staging in favorable histology wilms tumor.
        J Pediatr Surg. 2019; 54: 2331-2335https://doi.org/10.1016/j.jpedsurg.2019.06.010
        • Saltzman AF
        • Smith DE
        • Gao D
        • Cost NG.
        Lymph node yield in pediatric, adolescent and young adult renal cell carcinoma - how many are enough?.
        J Pediatr Surg. 2020; 55: 2030-2034https://doi.org/10.1016/j.jpedsurg.2020.04.004
      2. AREN1721: A randomized phase 2 trial of Axitinib/Nivolumab combination therapy vs single agent axitinib or nivolumab for the treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) across all age groups. Available at: https://www.childrensoncologygroup.org/aren1721. Accessed September 15, 2022